A. Chodacki

发表

Alpha emitter radium-223 and survival in metastatic prostate cancer.

I Syndikus, J Kliment, S. Fosså, 2013, The New England journal of medicine.

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

D. Amadori, S. Fosså, C. Parker, 2011 .

A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.

C. Parker, P. Hoskin, J. O’Sullivan, 2013, European urology.

684 RADIUM-223 CHLORIDE (ALPHARADIN) IMPACT ON OVERALL SURVIVAL AND SKELETAL-RELATED EVENTS IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER WITH BONE METASTASES A PHASE III RANDOMIZED TRIAL (ALSYMPCA)

C. Parker, N. James, P. Hoskin, 2012 .

130 Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: A phase III randomized trial (ALSYMPCA)

S. Fosså, C. Parker, N. James, 2012 .

Pembrolizumab in II. line therapy of metastatic BRAF-mutated malignant melanomaCase report of long-term remission after vemurafenib treatment failure

A. Chodacki, David Šulc, Jana Pukyová, 2017 .

Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

S. Fosså, C. Parker, N. James, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

D. Amadori, S. Fosså, A. Haese*, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The n e w e n g l a n d j o u r n a l of m e d i c i n e Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

S. Fosså, D. Bottomley, J. Logue, 2022 .

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

S. Fosså, C. Parker, N. James, 2017, European urology.

Preparation and quality control of [166Ho]-macroaggregates for radiosynoviorthesis.

O. Kraft, A. Chodacki, F. Melichar, 2007, Cancer biotherapy & radiopharmaceuticals.

Preparation and Quality Control of ( 166 Ho)-Macroaggregates for Radiosynoviorthesis

O. Kraft, A. Chodacki, F. Melichar, 2007 .

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

S. Fosså, C. Parker, N. James, 2014, The Lancet. Oncology.

Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA).

S. Fosså, C. Parker, N. James, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA).

S. Fosså, C. Parker, P. Hoskin, 2012 .

Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

Sten Nilsson, Arne Solberg, Joe M O'Sullivan, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA).

S. Fosså, C. Parker, N. James, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

101 Updated analysis of radium-223 dichloride (Ra-223) impact on pain, skeletal-related events (SRE), and survival from the phase 3 randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) and bone metastases

C. Parker, D. Heinrich, S. Helle, 2013 .